BioSpace News Archive

Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, announced it will present at the upcoming H.C. Wainwright Global Investment Conference, which is being held on September 11th-13th, 2023.

Vistagen and Fuji Pharma Co., Ltd. announced they have entered into a time-limited agreement to negotiate exclusively with each other regarding a potential license to develop and commercialize Vistagen’s PH80 in Japan, including for the acute treatment of moderate to severe vasomotor symptoms due to menopause and potentially other indications.

VesiCURE Therapeutics Co. Ltd., a biotechnology company located in Suzhou, China, recently released a preprint on BioRxiv titled “Harnessing extracellular vesicles for efficient siRNA delivery in vitro and in vivo” (doi: https://doi.org/10.1101/2023.08.26.554924).

Biophytis SA (Nasdaq CM:BPTS, Euronext Growth Paris:ALBPS), (“Biophytis” or the “Company”) announces that its CEO, Stanislas Veillet, will participate and hold a presentation at the “H.C. Wainwright 25th Annual Global Investment Conference”, which takes place from September 11 to 13, 2023 in New York.

SIBIONICS, a leader in bio-wearable consumer electronics, is pleased to announce the launch of SIBIO KS1 Continuous Ketone Monitoring (CKM) System, the company’s newest biometric wearable device designed to measure ketone levels.

CNS Pharmaceuticals, Inc. today announced that John Climaco, CEO of CNS Pharmaceuticals, will present at the H.C. Wainwright 25th Annual Global Investment Conference being held in New York, NY on Wednesday, September 13, 2023 at 10:30 AM ET.

Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast cancers harboring ESR1 mutations, today announced it shared an encore poster presentation at the 10th annual Metastatic Breast Cancer Research Conference (MBCRC) highlighting the results of its Phase 2 ELAINE-2 clinical study.

Solid Biosciences Inc. today announced that Bo Cumbo, President and Chief Executive Officer, will participate in the following two upcoming investor conferences.

10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that its technologies were used in a study published in the Journal of Clinical Investigation to explain why immune checkpoint blockade, a type of immunotherapy, is more effective for treating cancers that spread to the brain than it is for cancers that originate in the brain, like glioblastoma.

Exactech announced first cases with the TriVerse™ primary knee system, an evidence-based, streamlined solution that is designed to address the ever-increasing demands of ’s active knee replacement patients.